Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium
Author(s): Jones Marty
Issue: Jan/Feb 2000 - Compounding for Pain Management
View All Articles in Issue
Page(s): 6-15
Download in electronic PDF format for $65
Abstract: Recent reports of N-methyl-D-aspartate receptor antagonists, glutamate antagonists, alpha2-agonists, gamma-aminobutyric acid agonists, alpha1-antagonists, opioids and antioxidants in various combinations provide the contemporary rationale that is furnishing increased efficacy in the clinical management of chronic neuropathic pain, with fewer side effects. This article focuses on this new theory as an approach, from the perspective of a compounding pharmacist, to provide better control of chronic neuropathic pain in the new millennium. Implementation of this theory in daily practice within the triad of care will enhance the odds of positive outcomes in patients suffering from chronic neuropathic pain. The author focuses on pathophysiology, evidence, a new approach and clinical compounding success. He concludes that this is a huge market and that the efficacy is significant using the approach presented in this article.
Related Keywords: allodynia, amantadine, AMPA receptors, baclofen, carbamazepine, clonidine, compounding, DermiGel, dermis, dextromethorphan, diabetic peripheral neuropathy, epidermis, fibromyalgia, free radicals, GABA receptors, gapabentin, HbA1c, hyperalgesia, ketamine, memantine, neuropathic pain, nifedipine, NMDA receptors, opioids, opium, orphenadrine, pain, pain management, phenytoin, PLO, postherpetic neuralgia, prazosin, reflex sympathetic dystrophy, speed gel, tricyclic antidepressants, valproic acid, VanPen, dermatome